These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 20663001)

  • 1. The improper use of research placebos.
    Kottow M
    J Eval Clin Pract; 2010 Dec; 16(6):1041-4. PubMed ID: 20663001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III trials: specific problems associated with the use of a placebo control group.
    Cleophas TJ; Van der Meulen J; Kalmansohn RB
    Int J Clin Pharmacol Ther; 1997 Feb; 35(2):47-50. PubMed ID: 9147706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of placebos in phase III clinical trials in Brazil.
    Rubenich GB; Heck ST; Hellmann F; Schlemper Junior BR
    Salud Colect; 2015 Mar; 11(1):99-114. PubMed ID: 25853833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Phase III trials in oncology].
    Imadalou K; Cvitkovic E
    Bull Cancer; 1999 Feb; 86(2):143-7. PubMed ID: 10066944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of randomized controlled trials.
    Stanley K
    Circulation; 2007 Mar; 115(9):1164-9. PubMed ID: 17339574
    [No Abstract]   [Full Text] [Related]  

  • 6. The placebo effect.
    Watson R
    J Clin Nurs; 2006 May; 15(5):519. PubMed ID: 16629958
    [No Abstract]   [Full Text] [Related]  

  • 7. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical equipoise and randomised clinical trials in oncology].
    Ferté C; Hollebecque A; Salleron J; Penel N
    Bull Cancer; 2009 Jun; 96(6):727-31. PubMed ID: 19470421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 25-year review of sequential methodology in clinical studies.
    Todd S
    Stat Med; 2007 Jan; 26(2):237-52. PubMed ID: 17139691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges and opportunities: what we are learning from the clinical natalizumab experience.
    Kachuck NJ
    Expert Rev Neurother; 2005 Sep; 5(5):605-15. PubMed ID: 16162084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The phase III candidate: can we improve the science of selection?
    Bajorin D
    J Clin Oncol; 2004 Jan; 22(2):211-3. PubMed ID: 14665614
    [No Abstract]   [Full Text] [Related]  

  • 12. Bayesian sample size determination in non-sequential clinical trials: Statistical aspects and some regulatory considerations.
    Grouin JM; Coste M; Bunouf P; Lecoutre B
    Stat Med; 2007 Nov; 26(27):4914-24. PubMed ID: 17559054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Processes to activate phase III clinical trials in a cooperative oncology group: the elephant is monstrous.
    Steensma DP
    J Clin Oncol; 2007 Mar; 25(9):1148; author reply 1148-9. PubMed ID: 17369584
    [No Abstract]   [Full Text] [Related]  

  • 14. Flexible design of two-stage adaptive procedures for phase III clinical trials.
    Koyama T
    Contemp Clin Trials; 2007 Jul; 28(4):500-13. PubMed ID: 17307399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adaptive biased-coin designs for skewing the allocation proportion in clinical trials with normal responses.
    Atkinson AC; Biswas A
    Stat Med; 2005 Aug; 24(16):2477-92. PubMed ID: 16007571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical trials as treatment option: bioethics and health care disparities in substance dependency.
    Timmermans S; McKay T
    Soc Sci Med; 2009 Dec; 69(12):1784-90. PubMed ID: 19819059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re: Design and endpoints of clinical trials in hepatocellular carcinoma.
    Di Maio M; Daniele B; Gallo C; Perrone F
    J Natl Cancer Inst; 2008 Nov; 100(21):1557; author reply 1557-8. PubMed ID: 18957679
    [No Abstract]   [Full Text] [Related]  

  • 18. The ethics of early stopping rules.
    Pater J; Goss P; Ingle J; Shelley W; Shepherd L
    J Clin Oncol; 2005 Apr; 23(12):2862-3; author reply 2863-4. PubMed ID: 15838002
    [No Abstract]   [Full Text] [Related]  

  • 19. Scientific and ethical considerations in trial design for investigational agents for the treatment of human immunodeficiency virus infection.
    Feinberg J; Japour AJ
    Clin Infect Dis; 2003 Jan; 36(2):201-6. PubMed ID: 12522753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Likelihood inference for a two-stage design with treatment selection.
    Bebu I; Luta G; Dragalin V
    Biom J; 2010 Dec; 52(6):811-22. PubMed ID: 20818645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.